Spero Therapeutics, Inc. (SPRO) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 258K | 39.66M | 3.05M | 11.8M | 5.87M | 15.04M | 13.47M | 10.2M | 4.2M | 73.52M | 25.47M | 2.72M |
| Revenue Growth % | -95.61% | 163.61% | -77.37% | 15.74% | 39.72% | -79.54% | -47.12% | 275.44% | 103.19% | 58.61% | 2254.25% | 203.13% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 13.61M | 94.63M | 0 | 23.73M | 0 | 49.43M | 619K | 9.51M |
| COGS % of Revenue | - | - | - | - | 231.63% | 629.05% | - | 232.67% | - | 67.24% | 2.43% | 350.15% |
| Gross Profit | 258K | 39.66M | 3.05M | 11.8M | -7.73M | -79.59M | 13.47M | -13.53M | 4.2M | 24.09M | 24.85M | -6.79M |
| Gross Margin % | 100% | 100% | 100% | 100% | -131.63% | -529.05% | 100% | -132.67% | 100% | 32.76% | 97.57% | -250.15% |
| Gross Profit Growth % | 103.34% | 149.83% | -77.37% | 187.24% | -283.92% | -430.41% | -45.81% | -99.12% | 160.84% | -48.03% | 2197.04% | -858.26% |
| Operating Expenses | 7.8M | 8.25M | 10.96M | 14.25M | 7M | -57.87M | 32.06M | 5.53M | 18.19M | -26.44M | 26.79M | 6.1M |
| OpEx % of Revenue | 3021.71% | 20.81% | 359.71% | 120.71% | 119.15% | -384.64% | 238.04% | 54.26% | 432.59% | -35.97% | 105.16% | 224.45% |
| Selling, General & Admin | 4.89M | 4.3M | 4.17M | 5.88M | 6.82M | 7.06M | 5.2M | 5.53M | 5.92M | 6.43M | 5.71M | 6.1M |
| SG&A % of Revenue | 1894.19% | 10.84% | 136.94% | 49.81% | 116.17% | 46.9% | 38.59% | 54.26% | 140.75% | 8.75% | 22.41% | 224.45% |
| Research & Development | 2.91M | 5.59M | 8.6M | 10.67M | 13.61M | 28.84M | 26.86M | 23.73M | 17.33M | 16.56M | 16.39M | 9.51M |
| R&D % of Revenue | 1127.52% | 14.1% | 282.05% | 90.43% | 231.63% | 191.68% | 199.45% | 232.67% | 412.27% | 22.52% | 64.35% | 350.15% |
| Other Operating Expenses | 0 | -1000K | -1000K | -1000K | -1000K | -1000K | 0 | -1000K | -1000K | -1000K | 1000K | -1000K |
| Operating Income | -7.54M | 31.41M | -7.92M | -2.44M | -14.73M | -21.73M | -18.59M | -19.06M | -13.98M | 50.53M | -1.93M | -12.89M |
| Operating Margin % | -2921.71% | 79.19% | -259.71% | -20.71% | -250.78% | -144.41% | -138.04% | -186.93% | -332.59% | 68.73% | -7.59% | -474.59% |
| Operating Income Growth % | 48.83% | 244.56% | 57.42% | 87.18% | -5.36% | -142.99% | -861.38% | -47.87% | 1.72% | 94.92% | 83.66% | 50.58% |
| EBITDA | -7.54M | 31.41M | -7.38M | -2.36M | -14.73M | -20.85M | -18.59M | -19.06M | -13.98M | 50.57M | -1.83M | -12.78M |
| EBITDA Margin % | -2921.71% | 79.19% | -242.19% | -20.01% | -250.77% | -138.58% | -138.03% | -186.92% | -332.59% | 68.78% | -7.17% | -470.62% |
| EBITDA Growth % | 48.83% | 250.64% | 60.29% | 87.61% | -5.35% | -141.23% | -918.13% | -49.12% | 0.94% | 94.1% | 84.23% | 50.43% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 500 | 0 | 2K | 1K | 0 | 38K | 108K | 108K |
| EBIT | -7.54M | 31.41M | -7.38M | -2.36M | -14.56M | -20.85M | -18.59M | -19.06M | -13.98M | 50.53M | 3.37M | -12.89M |
| Net Interest Income | 336K | 376K | 532K | 740K | 864K | 1.03M | 1.18M | 1.2M | 1.33M | 1.04M | 950K | 982K |
| Interest Income | 336K | 376K | 532K | 740K | 864K | 1.03M | 1.18M | 1.2M | 1.33M | 1.04M | 950K | 982K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 335K | 376K | 534K | 744K | 865K | 1.13M | 1.16M | 1.2M | 1.31M | 1.05M | 940K | 976K |
| Pretax Income | -7.2M | 31.78M | -7.38M | -1.7M | -13.87M | -20.6M | -17.44M | -17.86M | -12.67M | 51.58M | -994K | -11.91M |
| Pretax Margin % | -2791.86% | 80.14% | -242.19% | -14.4% | -236.06% | -136.92% | -129.46% | -175.17% | -301.36% | 70.15% | -3.9% | -438.66% |
| Income Tax | 0 | 261K | 0 | 0 | 0 | 290K | -290K | 0 | 0 | 387K | 2.21M | 0 |
| Effective Tax Rate % | 0% | 0.82% | 0% | 0% | 0% | -1.41% | 1.66% | 0% | 0% | 0.75% | -222.43% | 0% |
| Net Income | -7.2M | 31.52M | -7.38M | -1.7M | -13.87M | -20.89M | -17.15M | -17.86M | -12.67M | 51.19M | -3.21M | -11.91M |
| Net Margin % | -2791.86% | 79.48% | -242.19% | -14.4% | -236.06% | -138.85% | -127.31% | -175.17% | -301.36% | 69.63% | -12.58% | -438.66% |
| Net Income Growth % | 48.05% | 250.9% | 56.95% | 90.48% | -9.45% | -140.8% | -435.01% | -49.92% | 4.5% | 91.22% | 72.55% | 58.46% |
| Net Income (Continuing) | -7.2M | 31.52M | -7.38M | -1.7M | -13.87M | -20.89M | -17.15M | -17.86M | -12.67M | 51.19M | -3.21M | -11.91M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.13 | 0.53 | -0.13 | -0.03 | -0.25 | -0.39 | -0.32 | -0.33 | -0.24 | 0.96 | -0.06 | -0.23 |
| EPS Growth % | 48% | 235.9% | 59.38% | 90.82% | -4.17% | -140.63% | -426.32% | -43.48% | -4.35% | 74.55% | 81.58% | 73.56% |
| EPS (Basic) | -0.13 | 0.56 | -0.13 | -0.03 | -0.25 | -0.39 | -0.32 | -0.33 | -0.24 | 0.97 | -0.06 | -0.23 |
| Diluted Shares Outstanding | 57.28M | 59.37M | 56.28M | 56.03M | 55.38M | 54.04M | 54.12M | 53.96M | 53.52M | 53.11M | 52.71M | 52.57M |
| Basic Shares Outstanding | 57.28M | 56.02M | 56.28M | 56.03M | 55.38M | 54.04M | 54.12M | 53.96M | 53.52M | 53M | 52.71M | 52.57M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |